ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Sangamo Therapeutics Inc

Sangamo Therapeutics Inc (SGMO)

2.56
-0.07
(-2.66%)
Cerrado 28 Diciembre 3:00PM
2.57
0.01
(0.39%)
Fuera de horario: 6:46PM

Calls

StrikeCompraVentaUltimo PrecioP. MedioVariaciónVariación %VolumeInt AbiertoÚltimo Operado
0.501.652.352.202.000.000.00 %1827/12/2024
1.001.501.751.401.6250.000.00 %0141-
1.500.351.301.050.8250.000.00 %0207-
2.000.650.850.760.750.000.00 %102,78127/12/2024
3.000.100.300.240.20-0.01-4.00 %1783,89227/12/2024
4.000.050.100.100.0750.05100.00 %12561527/12/2024
5.000.050.050.050.050.000.00 %095-

Herramientas de nivel profesional para inversores individuales.

Puts

StrikeCompraVentaUltimo PrecioP. MedioVariaciónVariación %VolumeInt AbiertoÚltimo Operado
0.500.000.050.000.000.000.00 %00-
1.000.050.100.050.0750.000.00 %01-
1.500.050.050.050.050.000.00 %049-
2.000.050.150.100.10-0.02-16.67 %25674827/12/2024
3.000.550.650.630.600.0610.53 %2032327/12/2024
4.001.301.601.701.450.000.00 %01-
5.002.252.802.612.5250.000.00 %010-

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
INTZIntrusion Inc
US$ 2.167
(381.56%)
189.59M
AILEiLearningEngines Inc
US$ 0.5932
(267.31%)
563.26M
HUBCWHub Cyber Security Ltd
US$ 0.035
(250.00%)
2.79M
GTIGraphjet Technology
US$ 0.967551
(185.83%)
398.95M
LITMSnow Lake Resources Ltd
US$ 1.61
(82.95%)
131.98M
NEUPNeuphoria Therapeutics Inc
US$ 4.11
(-92.30%)
940.73k
VIRXViracta Therapeutics Inc
US$ 0.16
(-32.49%)
9.47M
PRFXPainReform Ltd
US$ 3.48
(-28.98%)
949.52k
AIREreAlpha Tech Corporation
US$ 2.56
(-28.49%)
8.42M
AVGRAvinger Inc
US$ 0.9721
(-24.05%)
2.16M
AILEiLearningEngines Inc
US$ 0.5932
(267.31%)
557.72M
GTIGraphjet Technology
US$ 0.967551
(185.83%)
398.75M
RGTIRigetti Computing Inc
US$ 17.08
(10.62%)
298.47M
XTIAXTI Aerospace Inc
US$ 0.03935
(-1.63%)
263.01M
QSIQuantum Si Inc
US$ 3.585
(66.74%)
250.36M

SGMO Discussion

Ver más
stockprofitter stockprofitter 4 días hace
New 52wk highs coming soon
👍️0
Monksdream Monksdream 7 días hace
SGMO under $3
👍️0
georgie18 georgie18 1 semana hace
SGMO...$2.87...🥳Looking for the $3 Breakout...Last run from .30 to $3...

georgie18

Member Level
Re: None

Friday, December 13, 2024 9:33:14 AM

Post#
980
of 984
SGMO...$2.11...Starting up again...🥳
👍️0
glenn1919 glenn1919 1 semana hace
sgmo...............https://stockcharts.com/h-sc/ui?s=sgmo&p=W&b=5&g=0&id=p86431144783
👍️0
harr449 harr449 2 semanas hace
Something going on. Up again. $2.72. Up 3%.
👍️0
georgie18 georgie18 2 semanas hace
SGMO...$2.66...🥳...on the Breakout...
👍️0
georgie18 georgie18 2 semanas hace
SGMO...$2.50...🥳...Trying for Upper Bollie Breakout here...
👍️0
georgie18 georgie18 2 semanas hace
SGMO...$2.11...Starting up again...🥳
👍️0
PonkenPlonken PonkenPlonken 4 semanas hace
Career site shows just 2 temporary positions for weeks?
Maybe has momo till december 9 presentation of the ph3 in HEM A with Pfizer.
👍️0
PonkenPlonken PonkenPlonken 4 semanas hace
May go to 4 first but valuation makes no sense - overbought zinc finger dud.
Smart and extensive promotion campaign by management.
👍️0
Mactheriverrat Mactheriverrat 1 mes hace
SGMO - Nice day and the start of another uptrend
👍️0
glenn1919 glenn1919 1 mes hace
SGMO...........................https://stockcharts.com/h-sc/ui?s=SGMO&p=W&b=5&g=0&id=p86431144783
👍️ 1
1-1 is 4 1-1 is 4 1 mes hace
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
BUSINESS WIRE 4:15 PM ET 11/19/2024
👍️0
1-1 is 4 1-1 is 4 1 mes hace
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target
BENZINGA 1:20 PM ET 11/14/2024
👍️0
glenn1919 glenn1919 1 mes hace
sgmo.............................https://stockcharts.com/h-sc/ui?s=SGMO&p=W&b=5&g=0&id=p86431144783
👍️0
molee molee 1 mes hace
$SGMO > So-So earnings report brings out the sharks ...

Where will it settle ???
👍️0
georgie18 georgie18 1 mes hace
SGMO...$2.33...🥳...https://ih.advfn.com/stock-market/NASDAQ/sangamo-therapeutics-SGMO/stock-news/94894589/form-s-3-registration-statement-under-securities
👍️0
georgie18 georgie18 2 meses hace
SGMO...$2.53...Fins after close...🥳

georgie18

Member Level
Re: georgie18 post# 664188

Friday, November 08, 2024 11:09:45 AM

Post#
664225
of 664553
SGMO...$3.10s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 385366

Friday, November 08, 2024 9:21:06 AM

Post#
385382
of 385395
SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...

georgie18

Member Level
Re: georgie18 post# 663989

Thursday, November 07, 2024 2:23:36 PM

Post#
664113
of 664186
SGMO...$2.83...🥳

georgie18

Member Level
Re: georgie18 post# 385311

Thursday, November 07, 2024 9:59:59 AM

Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳

georgie18

Member Level
Re: georgie18 post# 663756

Wednesday, November 06, 2024 2:50:09 PM

Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
👍️0
georgie18 georgie18 2 meses hace
Have a Great Weekend Y'all...🥳
👍️0
molee molee 2 meses hace
$SGMO earnings 11/12 . After market closes . 🚀🔥🏃💲

Enjoy the holiday weekend . >> M
👍️ 1 😃 1
georgie18 georgie18 2 meses hace
SGMO...$3.10s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 385366

Friday, November 08, 2024 9:21:06 AM

Post#
385382
of 385395
SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...

georgie18

Member Level
Re: georgie18 post# 663989

Thursday, November 07, 2024 2:23:36 PM

Post#
664113
of 664186
SGMO...$2.83...🥳

georgie18

Member Level
Re: georgie18 post# 385311

Thursday, November 07, 2024 9:59:59 AM

Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳

georgie18

Member Level
Re: georgie18 post# 663756

Wednesday, November 06, 2024 2:50:09 PM

Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
👍️ 1
georgie18 georgie18 2 meses hace
SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...

georgie18

Member Level
Re: georgie18 post# 663989

Thursday, November 07, 2024 2:23:36 PM

Post#
664113
of 664186
SGMO...$2.83...🥳

georgie18

Member Level
Re: georgie18 post# 385311

Thursday, November 07, 2024 9:59:59 AM

Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳

georgie18

Member Level
Re: georgie18 post# 663756

Wednesday, November 06, 2024 2:50:09 PM

Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
👍️ 1
INV4 INV4 2 meses hace
Another great day 😃

$SGMO
👍️0
georgie18 georgie18 2 meses hace
SGMO...$2.83...🥳

georgie18

Member Level
Re: georgie18 post# 385311

Thursday, November 07, 2024 9:59:59 AM

Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳

georgie18

Member Level
Re: georgie18 post# 663756

Wednesday, November 06, 2024 2:50:09 PM

Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
👍️0
georgie18 georgie18 2 meses hace
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳

georgie18

Member Level
Re: georgie18 post# 663756

Wednesday, November 06, 2024 2:50:09 PM

Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
👍️0
georgie18 georgie18 2 meses hace
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf

SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
👍️0
molee molee 2 meses hace
$SGMO at $2.33 is in BEAST mode > 🦍🚀🔥💲
👍️0
georgie18 georgie18 2 meses hace
SGMO...$2.25...🥳

georgie18

Member Level
Re: georgie18 post# 663703

Tuesday, November 05, 2024 3:35:51 PM

Post#
663735
of 663755
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
👍️0
INV4 INV4 2 meses hace
Nice! 😃

$SGMO
👍️0
glenn1919 glenn1919 2 meses hace
SGMO......................................https://stockcharts.com/h-sc/ui?s=SGMO&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 2 meses hace
SGMO...$2.14...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 663630

Tuesday, November 05, 2024 1:25:37 PM

Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
👍️0
georgie18 georgie18 2 meses hace
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).

The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.



Member Level
Re: georgie18 post# 663012

Monday, November 04, 2024 4:27:39 PM

Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
👍️0
saigai saigai 2 meses hace
they keep wacking the 2 dollars.. please sell and get out of the way thank you
👍️0
georgie18 georgie18 2 meses hace
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
Your statement implies we have ANY effect on how either SGMO or OMGA are trading. We dont.

The companies arent related at all. SGMO is zinc fingers and OMGA is oncology and obesity.
OMGA has Novo Nordisk, SGMO has Genentech. SGMO trades at ~9x the market cap of OMGA. Its not a secret that sometimes theres a bidding war around assets or entire companies. That means if a company is desirable, the bidder with the deepest pockets will come out on top.
👍️0
KIPK KIPK 2 meses hace
Ponken, Bashing this to help your OMGA Investment?? LOL...

OMGA is years away & anything mRNA based is tented with serious safety issues imo
👍️0
PonkenPlonken PonkenPlonken 2 meses hace
a lot of momentum here..... I believe too much.
Sitting at 400m market cap, ~1 quarter left in cash and 150m operating expense per year
👍️0
molee molee 2 meses hace
SGMO Upcoming Quarter's Earnings >>> Maybe . ( I know , we wait )
Announce Date
11/8/2024 (Post-Market)

Says Seeking Alpha : https://seekingalpha.com/symbol/SGMO/earnings
👍️0
INV4 INV4 2 meses hace
Agree Molee! Have a great weekend 😃

$SGMO
👍️0
molee molee 2 meses hace
$SGMO has held up remarkably well considering all the shorts / sharks in the waters .

Enjoy the weekend team >> M
👍️ 1
KIPK KIPK 2 meses hace
According to TD Its Friday, 1st Nov..??

CC at 4:30 AM
Earning at 9:30 AM
👍️0
molee molee 2 meses hace
Thanks . Fidelity shows today , but that's not always correct .
👍️0
teifhals teifhals 2 meses hace
No - they will announce when they will announce earnings. They have not yet made the Q3 announcement. Probably wrapping up something first.
👍️0
molee molee 2 meses hace
I think earnings report is due out today / soon ?
👍️0
KIPK KIPK 2 meses hace
jondoeuk,

Is the company you representing have been shorting SGMO???

hummmmm
👍️0
INV4 INV4 2 meses hace
Good morning and thank you jondoeuk. Many of these types of companies struggle at first, but when they have a 'hit', things can turn around quickly. We'll have to wait and see IMHO.
Unless they upgrade their tech to include additional tools
News Release:

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025

October 22, 2024

- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.

- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.

- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.

RICHMOND, Calif.--(BUSINESS WIRE)--Oct. 22, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the outcome of a recent successful interaction with the U.S. FDA, providing a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec, or ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease...

https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-announces-alignment-fda-accelerated

$SGMO
👍️0
jondoeuk jondoeuk 2 meses hace
Pioneering the future of genomic medicine? The company was founded in 1995. Gene editing has evolved. Unless they upgrade their tech to include additional tools I can't seem them being a meaningful player in any way. Too many failures* in their long history. Another issue is the management.

* This includes diabetic neuropathy, HIV, IVPRP, TDT/SCD, oncology (with GILD), and CNS (with BIIB and NVS). Investments in CAR-Tregs (and elsewhere) were written off. Also, programs in Huntington's, ALS, and others that still have not gotten off the ground. They were touting base editing at one point. But not to worry, they pivoted again!
👍️ 1
glenn1919 glenn1919 2 meses hace
SGMO...............................https://stockcharts.com/h-sc/ui?s=SGMO&p=W&b=5&g=0&id=p86431144783
👍️ 1
molee molee 2 meses hace
Still very good volume .. Higher highs and higher lows ...
👍️ 1 💯 1
georgie18 georgie18 2 meses hace
Thanks...🥳
👍️0

Su Consulta Reciente

Delayed Upgrade Clock